116P Clinical utility and impact on outcomes of upfront circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): A real-world (RW) study

Key Points

To assess the efficacy and safety of combining UV1 vaccine with PD-1 inhibitors in advanced non-small cell lung cancer.
Enrolled patients with stage IIIB/C or IV non-small cell lung cancer eligible for PD-1 inhibitor monotherapy.
Randomized patients to receive standard of care alone or in combination with UV1 + GM-CSF vaccinations.
Measured primary endpoint of progression free survival and secondary endpoints of overall survival and safety.
No significant benefit in progression free survival between UV1 + SoC and SoC alone (8 mo vs 7 mo).
Overall survival not reached for UV1 + SoC; 24 months for SoC with a numerical advantage observed.
Twelve-month overall survival rates were 73.3% (UV1 + SoC) and 60% (SoC).
Average time to response was 2 months for UV1 + SoC and 3 months for SoC.
Adverse events occurred in 90% of patients, with a higher incidence in the UV1 + SoC arm.

This randomized trial evaluates combined immunotherapy impact on survival in advanced lung cancer, suggesting further exploration is needed.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Rota et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share